Recruitment

Recruitment Status
Recruiting
Estimated Enrollment
Same as current

Summary

Conditions
  • Hepatitis C
  • Substance Use Disorders
Type
Observational
Design
Observational Model: CohortTime Perspective: Prospective

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Description

This is a cohort of people who inject drugs with chronic HCV infection. Patients are seen at a low-threshold clinic. All patients are offered treatment for HCV and subsequently followed for to years Inclusion Consenting patients older than 18 years attending the low threshold HCV clinic in Oslo The ...

This is a cohort of people who inject drugs with chronic HCV infection. Patients are seen at a low-threshold clinic. All patients are offered treatment for HCV and subsequently followed for to years Inclusion Consenting patients older than 18 years attending the low threshold HCV clinic in Oslo The primary aims are to assess the efficacy (SVR rate) of DAA treatment among PWID treated in a low-threshold primary care setting (Work Package 1) and to estimate the incidence HCV reinfection f The secondary aims are to: Evaluate adherence to DAA treatment (Work Package 1) Identify factors associated with SVR and adherence (Work Package 1) Characterize reinfection using next generation sequencing (Work Package 2) Identify factors associated with reinfection (Work Package 2) Evaluate changes in recent injecting risk behaviours longitudinally (Work Package 2) Identify factors associated with changes in risk behaviours (Work Package 2) The hypothesis is that high SVR rates and good treatment adherence will be achieved in PWID treated for HCV infection in a low-threshold primary health care setting. Further,it is anticipated that the incidence of reinfection will be 5-10/100 PY and associated with younger age, low education level and ongoing injecting risk behaviours. The study will include 300 patients and are close to achieving that aim the summer of 2019

Tracking Information

NCT #
NCT04063839
Collaborators
Not Provided
Investigators
Study Chair: Olav Dalgard, MD PhD University Hospital, Akershus